{"url_path":"/sec/mgtx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1735438/0001104659-26-060739-index.html","accession_number":"0001104659-26-060739","cik":"0001735438","ticker":"MGTX","issuer_name":"MeiraGTx Holdings plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1735438/0001104659-26-060739-index.html","primary_entity_key":"0001735438","primary_entity_name":"MeiraGTx Holdings plc"},"word_count":1825,"has_tables":true,"body_markdown":"MeiraGTx Holdings plc_March 31, 2026\n\n0001735438--12-312026Q1false8112093181446126P5DP6M1P10Y0.250000http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember0001735438us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001735438us-gaap:CommonStockMember2025-01-012025-03-310001735438us-gaap:CommonStockMember2026-01-012026-03-310001735438us-gaap:TreasuryStockCommonMember2026-03-310001735438us-gaap:RetainedEarningsMember2026-03-310001735438us-gaap:AdditionalPaidInCapitalMember2026-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001735438us-gaap:RetainedEarningsMember2025-12-310001735438us-gaap:AdditionalPaidInCapitalMember2025-12-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001735438us-gaap:RetainedEarningsMember2025-03-310001735438us-gaap:AdditionalPaidInCapitalMember2025-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001735438us-gaap:RetainedEarningsMember2024-12-310001735438us-gaap:AdditionalPaidInCapitalMember2024-12-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001735438us-gaap:SubsequentEventMembermgtx:PublicOfferingMember2026-04-170001735438srt:MaximumMemberus-gaap:EmployeeStockOptionMembermgtx:EquityIncentives2018PlanMember2026-01-012026-03-3100017354382025-01-012025-12-310001735438us-gaap:RestrictedStockUnitsRSUMember2025-12-310001735438us-gaap:EmployeeStockOptionMembermgtx:EquityIncentives2018PlanMembermgtx:FirstAnniversaryMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:ThirdAnniversaryMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:SecondAnniversaryMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:FourthAnniversaryMember2026-01-012026-03-310001735438us-gaap:EmployeeStockOptionMembersrt:DirectorMembermgtx:EquityIncentives2018PlanMember2026-01-012026-03-310001735438us-gaap:EmployeeStockOptionMembermgtx:EquityIncentives2018PlanMembermgtx:OverThreeYearsMember2026-01-012026-03-310001735438mgtx:BankOfAmericaSecuritiesInc.Membermgtx:AtMarketOfferingMembermgtx:SalesAgreementMember2026-01-012026-03-310001735438mgtx:BankOfAmericaSecuritiesInc.Membermgtx:AtMarketOfferingMembermgtx:SalesAgreementMember2025-01-012025-03-310001735438mgtx:RelatedPartyServiceRevenueMember2026-01-012026-03-310001735438mgtx:RelatedPartyServiceRevenueMember2025-01-012025-03-310001735438mgtx:BankOfAmericaSecuritiesInc.Membersrt:MaximumMembermgtx:AtMarketOfferingMembermgtx:SalesAgreementMember2026-01-012026-03-310001735438mgtx:BankOfAmericaSecuritiesInc.Membersrt:MaximumMembermgtx:AtMarketOfferingMembermgtx:SalesAgreementMember2023-12-012023-12-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001735438us-gaap:EuropeanUnionMember2026-03-310001735438country:US2026-03-310001735438country:GB2026-03-310001735438us-gaap:EuropeanUnionMember2025-12-310001735438country:US2025-12-310001735438country:GB2025-12-310001735438us-gaap:RetainedEarningsMember2026-01-012026-03-310001735438us-gaap:RetainedEarningsMember2025-01-012025-03-310001735438mgtx:HologenLimitedMembermgtx:HologenNeuroAiLimitedMemberus-gaap:SubsequentEventMember2026-04-200001735438mgtx:MeiragtxNeuroUkLimitedMembermgtx:HologenNeuroAiLimitedMemberus-gaap:SubsequentEventMember2026-04-200001735438mgtx:TermLoanMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2025-01-012025-03-310001735438us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001735438us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001735438us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001735438us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001735438mgtx:JohnsonAndJohnsonInnovationJjdcIncMemberus-gaap:SubsequentEventMembermgtx:AssetPurchaseAgreementMember2026-04-150001735438mgtx:FinancingAgreementMembermgtx:PerceptiveAdvisorsLlcMember2022-08-020001735438mgtx:VisiogeneLlcMember2026-03-310001735438mgtx:OtherEquityMethodInvestmentsMember2026-03-310001735438mgtx:VisiogeneLlcMember2025-03-310001735438mgtx:OtherEquityMethodInvestmentsMember2025-03-310001735438us-gaap:RestrictedStockUnitsRSUMember2026-03-310001735438us-gaap:EmployeeStockOptionMember2026-03-310001735438us-gaap:RestrictedStockUnitsRSUMember2025-03-310001735438us-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2026-03-310001735438mgtx:TermLoanMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2026-01-012026-03-310001735438mgtx:JanssenPharmaceuticalsIncMembermgtx:AssetPurchaseAgreementMember2025-12-310001735438us-gaap:CommonStockMember2026-03-310001735438us-gaap:CommonStockMember2025-12-310001735438us-gaap:CommonStockMember2025-03-310001735438us-gaap:CommonStockMember2024-12-310001735438us-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2026-03-250001735438mgtx:TermLoanMemberus-gaap:SecuredDebtMember2025-03-250001735438mgtx:ExercisePriceScenarioMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2022-08-020001735438mgtx:ExercisePriceScenarioBMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2022-08-0200017354382025-03-3100017354382024-12-310001735438mgtx:ResearchDevelopmentAndOtherAssetsMemberus-gaap:SubsequentEventMember2026-04-152026-04-150001735438us-gaap:WarrantMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001735438us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001735438us-gaap:WarrantMember2025-01-012025-03-310001735438us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001735438us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001735438us-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2026-01-012026-03-310001735438us-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2025-01-012025-03-310001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001735438us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001735438us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001735438us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001735438us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001735438us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001735438us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001735438us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001735438us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001735438us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001735438us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001735438us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001735438us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001735438us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001735438us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001735438mgtx:ShareRepurchaseAgreementWithPerceptiveLifeSciencesMasterFundLtdMember2025-12-310001735438mgtx:TermLoanMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2026-03-310001735438mgtx:ResearchDevelopmentAndOtherAssetsMemberus-gaap:SubsequentEventMember2026-04-150001735438mgtx:JanssenPharmaceuticalsIncMembermgtx:AssetPurchaseAgreementMember2026-03-310001735438srt:MinimumMembermgtx:GrantsIdaIrelandEmploymentMember2021-08-310001735438srt:MinimumMembermgtx:GrantsIdaIrelandCapitalMember2021-08-310001735438us-gaap:SubsequentEventMembermgtx:PublicOfferingMember2026-04-172026-04-170001735438mgtx:HologenLimitedMembermgtx:HologenTransactionAgreementMember2026-03-310001735438mgtx:HologenLimitedMemberus-gaap:SubsequentEventMembermgtx:HologenTransactionAgreementMember2026-04-012026-04-300001735438mgtx:HologenLimitedMembermgtx:HologenTransactionAgreementMember2025-03-092025-03-090001735438mgtx:HologenLimitedMembermgtx:HologenTransactionAgreementMember2025-01-012026-03-310001735438mgtx:HologenLimitedMembermgtx:HologenTransactionAgreementMember2025-01-012026-03-310001735438mgtx:HologenLimitedMembersrt:MaximumMembermgtx:HologenTransactionAgreementMember2025-03-092025-03-090001735438mgtx:HologenLimitedMembermgtx:MeiragtxManufacturingLimitedMemberus-gaap:SubsequentEventMember2026-04-200001735438srt:MinimumMember2026-01-012026-03-310001735438srt:MaximumMember2026-01-012026-03-310001735438srt:MaximumMembermgtx:GrantsIdaIrelandCapitalMember2021-08-012021-08-310001735438srt:MinimumMembermgtx:GrantsIdaIrelandEmploymentMember2021-08-012021-08-310001735438srt:MaximumMembermgtx:GrantsIdaIrelandEmploymentMember2021-08-012021-08-310001735438srt:MinimumMembermgtx:GrantsIdaIrelandMember2021-08-012021-08-310001735438srt:MaximumMembermgtx:GrantsIdaIrelandMember2021-08-012021-08-310001735438srt:MinimumMembermgtx:GrantsIdaIrelandCapitalMember2021-08-012021-08-310001735438mgtx:JanssenPharmaceuticalsIncMembermgtx:AssetPurchaseAgreementMember2025-01-012025-03-310001735438mgtx:TermLoanMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2022-08-020001735438us-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2022-08-020001735438mgtx:JanssenPharmaceuticalsIncMembermgtx:AssetPurchaseAgreementMember2026-01-012026-03-310001735438mgtx:EliLillyAndCompanyMembermgtx:EliLillyAndCompanyCollaborationAgreementMember2025-11-072025-11-070001735438mgtx:HologenLimitedMemberus-gaap:CollaborativeArrangementMember2025-03-090001735438mgtx:TermLoanMemberus-gaap:SecuredDebtMembermgtx:PerceptiveCreditHoldingsMember2022-08-022022-08-0200017354382025-01-012025-03-310001735438mgtx:JanssenPharmaceuticalsIncMembermgtx:AssetPurchaseAgreementMember2024-01-012024-12-310001735438mgtx:JanssenPharmaceuticalsIncMembermgtx:AssetPurchaseAgreementMember2023-01-012023-12-310001735438mgtx:MeiragtxManufacturingLimitedMembermgtx:JohnsonAndJohnsonInnovationJjdcIncMemberus-gaap:SubsequentEventMember2026-04-152026-04-150001735438mgtx:HologenLimitedMembermgtx:MeiragtxManufacturingLimitedMemberus-gaap:SubsequentEventMember2026-04-202026-04-200001735438mgtx:HologenLimitedMembermgtx:HologenTransactionAgreementMember2026-01-012026-03-3100017354382026-03-3100017354382025-12-3100017354382026-05-0800017354382026-01-012026-03-31xbrli:sharesiso4217:USDxbrli:pureiso4217:EURmgtx:cliniciso4217:USDxbrli:shares\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n**FORM ****10-Q**\n\n**(Mark One)**\n\n☒\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the quarterly period ended****March 31, 2026**\n\n**OR**\n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the transition period from****               ****  to****               **** **\n\n**Commission File Number:****001-38520**\n\n**MeiraGTx Holdings plc**\n\n**(Exact Name of Registrant as Specified in its Charter)**\n\n​\n\n​\n\n​\n\n​\n\n**Cayman Islands**\n\n  ​ ​ ​\n\n**98-1448305**\n\n**(State or other jurisdiction of**\n**incorporation or organization)**\n\n​\n\n**(I.R.S. Employer********Identification No.)**\n\n​\n\n​\n\n​\n\n**655 Third Avenue, Suite 1115******\n\n​\n\n​\n\n**New York****,****NY**\n\n​\n\n**10017**\n\n**(Address of principal executive offices)**\n\n​\n\n**(Zip Code)**\n\n​\n\n**Registrant’s telephone number, including area code: (****646****) ****860-7985**\n\n**Not Applicable**\n\n**(Former name, former address, and former fiscal year, if changed since last report)**\n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n​\n\n**Title of each class**\n\n  ​ ​ ​ ​\n\n**Trading**\n**Symbol(s)**\n\n  ​ ​ ​\n\n**Name of each exchange**\n**on which registered**\n\nOrdinary Shares,\n$0.00003881 par value per share\n\n​\n\nMGTX\n\n​\n\nThe Nasdaq Global Select Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer    ☐\n\n  ​ ​ ​\n\nAccelerated filer       ☐ \n\n​\n\n​\n\n​\n\nNon-accelerated filer     ☒\n\n​\n\nSmall reporting company        ☒\n\n​\n\n​\n\n​\n\n​\n\n​\n\nEmerging growth Company    ☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐    No  ☒\n\nAs of May 8, 2026, the registrant had 92,609,516 ordinary shares, $0.00003881 par value per share, outstanding.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\n**Forward-Looking Statements**\n\nThis Quarterly Report on Form 10-Q (the “Form 10-Q”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 10-Q that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding expectations regarding meetings with global regulatory authorities and the FDA, product pipeline, anticipated product benefits, goals and strategic transactions or priorities, product candidate development and status and expectations relating to clinical trials, growth expectations or targets, pre-clinical and clinical data expectations in respect of collaborations and expectations related to financing arrangements and the intended use of proceeds thereunder, as well as statements that include the words “expect,” “will,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “could,” “should,” “would,” “continue,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under “Item 1A. Risk Factors” in this Form 10-Q. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 10-Q. Any such forward-looking statements represent management’s estimates as of the date of this Form 10-Q. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Form 10-Q.\n\n​\n\ni\n\n[Table of Contents](#TOC)\n\n**Risk Factor Summary**\n\nWe are providing the following summary of the principal risk factors contained in this Form 10-Q to enhance the readability and accessibility of our risk factor disclosures. We encourage you to carefully review in their entirety the full risk factors set forth in the section of this Form 10-Q captioned “Part II—Item 1A. Risk Factors”**for additional information regarding the material factors that make an investment in our ordinary shares speculative or risky. These risks and uncertainties include, among others, the following:\n\n●We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future, and may never achieve or maintain profitability.\n\n●We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.\n\n●We may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements, or we may not be able to effectively manage our business in compliance with such covenants.\n\n●Our review of potential strategic transactions may not result in an executed or consummated transaction or other strategic alternative and may not result in anticipated benefits to us or our shareholders, and the process of reviewing strategic transactions or its conclusion could be disruptive and distracting to our business operations and management.\n\n●We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.\n\n●It is difficult to predict the time and cost of product candidate development on our novel gene therapy platform. A limited number of gene therapies have been approved in the United States or in Europe.\n\n●Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.\n\n●Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome. Further, we may encounter substantial delays in our clinical trials.\n\n●The affected populations for our product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.\n\n●We and our contract manufacturers for plasmid are subject to significant regulation with respect to manufacturing our products. Our manufacturing facilities and the third-party manufacturing facilities which we rely on may not continue to meet regulatory requirements and have limited capacity.\n\n●Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.\n\n●We are subject to regulation and other legal obligations relating to data privacy and protection. Compliance with these requirements is complex and costly.  The actual or perceived failure to comply with such obligations could materially harm our business.\n\n●We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are\n\nii\n\n[Table of Contents](#TOC)\n\nsafer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.\n\n●We depend on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our product candidates.\n\n●If we are unable to obtain and maintain patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.\n\n●We may need to increase or decrease the size of our organization, and we may experience difficulties in managing these organizational changes, which could disrupt our operations.\n\n●Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.\n\n​\n\n**Preliminary Notes**\n\nUnless the context otherwise requires, references in this Form 10-Q to “Meira,” “MeiraGTx,” “we,” “us”, “our” or “the Company” refer to MeiraGTx Holdings plc and its subsidiaries.\n\n​\n\nWe have proprietary rights to trademarks, trade names and service marks appearing in this Form 10-Q that are important to our business. Solely for convenience, the trademarks, trade names and service marks may appear in this Form 10-Q without the ® and TM symbols, but any such references are not intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners.\n\n​\n\niii\n\n[Table of Contents](#TOC)\n\n**Table of Contents**\n\n​\n\n​\n\n​\n\n**Page**\n\n[**PART I.**](#PARTIFINANCIALINFORMATION_819042)\n\n[**FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_819042)\n\n1\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1FinancialStatements_806846)\n\n[Financial Statements (Unaudited)](#Item1FinancialStatements_806846)\n\n1\n\n​\n\n[Condensed Consolidated Balance Sheets](#CONSOLIDATEDBALANCESHEETS_392522)\n\n1\n\n​\n\n[Condensed Consolidated Statements of Operations and Comprehensive Loss](#COMPREHENSIVELOSS_182033)\n\n2\n\n​\n\n[Condensed Consolidated Statement of Shareholders’ Deficit](#CONDENSEDCONSOLIDATEDSTATEMENTOFSHAREHOL)\n\n3\n\n​\n\n[Condensed Consolidated Statement of Shareholders’ Equity](#SHAREHOLDERSDEFICITEQUITY_618444)\n\n4\n\n​\n\n[Condensed Consolidated Statements of Cash Flows](#STATEMENTSOFCASHFLOWS_138361)\n\n5\n\n​\n\n[Notes to Condensed Consolidated Financial Statements](#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA)\n\n6\n\n[Item 2.](#Item2ManagementsDiscussionandAnalysisofF)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n29\n\n[Item 3.](#Item3QuantitativeandQualitativeDisclosur)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n43\n\n[Item 4.](#Item4ControlsandProcedures_891132)\n\n[Controls and Procedures](#Item4ControlsandProcedures_891132)\n\n44\n\n​\n\n​\n\n​\n\n[**PART II.**](#PARTIIOTHERINFORMATION_341431)\n\n[**OTHER INFORMATION**](#PARTIIOTHERINFORMATION_341431)\n\n45\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1LegalProceedings_709588)\n\n[Legal Proceedings](#Item1LegalProceedings_709588)\n\n45\n\n[Item 1A.](#Item1ARiskFactors_220365)\n\n[Risk Factors](#Item1ARiskFactors_220365)\n\n45\n\n[Item 2.](#Item2UnregisteredSalesofEquitySecurities)\n\n[Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](#Item2UnregisteredSalesofEquitySecurities)\n\n103\n\n[Item 3.](#Item3DefaultsUponSeniorSecurities_54116)\n\n[Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_54116)\n\n104\n\n[Item 4.](#Item4MineSafetyDisclosures_51301)\n\n[Mine Safety Disclosures](#Item4MineSafetyDisclosures_51301)\n\n104\n\n[Item 5.](#Item5OtherInformation_145683)\n\n[Other Information](#Item5OtherInformation_145683)\n\n104\n\n[Item 6.](#Item6Exhibits_373262)\n\n[Exhibits](#Item6Exhibits_373262)\n\n105\n\n​\n\n[Signatures](#SIGNATURES_71538)\n\n106\n\n​\n\n​\n\n​\n\n​\n\niv\n\n[Table of Contents](#TOC)\n\nPART I—FINANCIAL INFORMATION"}